Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

NCT03360630 PHASE1, PHASE2 COMPLETED

A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.

Details

Lead sponsor	Capital Medical University
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	60
Start date	Tue Nov 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jun 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lung Cancer
• Neoplasms

Interventions

• Anti-PD-1 plus DC-CIK
• Anti-PD-1 alone

Countries

China